Manufacturing, Parenterals and Injectables

When the expansion is completed, Piramal expects manufacturing capacity to be increased by the first quarter of 2027 from 104 product batches per year to more than 240.

This $4.1 billion investment to build a second fill/finish manufacturing facility in Clayton, N.C., boosts Novo Nordisk's current 2024 investments in production to $6.8 billion.

Lilly’s investment increase is intended to boost manufacturing capacity at its Lebanon, Ind., site for APIs used in the production of tirzepatide and other pipeline drug candidates.

CDMO White Raven aims to reduce contamination risk and gain the capability to handle multiple product formats with the installation of Cytiva’s SA25 Aseptic Filling Workcell.

Given the criticality of fill/finish processes, it is clear that automation is the next technological step.

The partnership will allow for both companies to provide end-to-end biopharmaceutical manufacturing solutions.

The company’s Itasca, Ill., facility will offer chemistry, manufacturing, and controls analytical testing support.

Biosynth has further strengthened its peptide division with the acquisition of Pepceuticals.

The newly established business under Advent International and Warburg Pincus will be named Simtra BioPharma Solutions.

Dosage forms are being shaped by numerous factors, with patient-centricity continuing to be an important driver of decisions in development.

Corning launches a more sustainable glass vial.

Kiefel’s new machine is designed to form, fill, and seal up to 6,000 infusion, parenteral nutrition, or dialysis bags per hour.

Shifts in pharmaceutical packaging have spurred tremendous growth in the pre-filled syringe fill/finish industry.

To prepare for emerging mRNA technologies, it is necessary to adapt fill/finish and cold chain capabilities.

Gerresheimer and Nelson Labs will work together to conduct extractables and leachables testing on upcoming primary packaging solutions.

Steriline will be exhibiting its vial filling and capping machine (VFCM100) under double-wall isolator for aseptic filling at CPHI 2022 in Frankfurt, Germany, on Nov. 1–3, 2022.

Recipharm’s new high speed filling line, designed for pre-filled syringes and cartridges, is expected to be operational by May 2023.

Product safety and security are paramount when it comes to container closures.

BFS technology can help maintain sterility during the biologics manufacturing process.

Choosing low-adsorption glass vials helps ensure detection accuracy.

Watson-Marlow and Franz Ziel GmbH have launched a new integrated solution to fast-track cell, gene, and biological therapies.

SCHOTT is planning to triple its ready-to-use vial production capacity in the United States to meet increasing demand for storing injectable drugs.

Demand spurs innovations in syringes and syringe fill/finish operations.

The inaugural Connect in Pharma event will take place on 14 and 15 September in Geneva, Switzerland.

Lubrizol has launched Apisolex technology to improve solubility and simplify the manufacturing of parenteral drug products.

PCI Pharma Services is investing $100 million in manufacturing capabilities and capacity expansion to its Bedford, NH facility.

Takeda’s TAKHZYRO prefilled syringe is now available for patients with hereditary angioedema aged 12 years and older in the United States.

Exhibitors display primary packaging, secondary packaging, and machine innovations at this year’s INTERPHEX.

The continuous, aseptic fill/finish process is finding use in vaccines and biologic drugs.

Curia and the US government have entered into a cooperative agreement to expand fill/finish capability for injectable medicines.